iBio has confirmed that its proprietary technology, the iBioLaunch platform, will help support a $5.3 million government-funded project for the development of a single vaccine to protect against both anthrax and plague. The project will be managed by Fraunhofer USA Center for Molecular Biotechnology pursuant to the long-term agreement between iBio and CMB for advancement of the iBio technology. Release